Bill Maughan
Stock Analyst at Clear Street
(n/a)
# 4,472
Out of 4,876 analysts
15
Total ratings
12.5%
Success rate
-44.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Downgrades: Hold | $45 | $47.49 | -5.24% | 1 | Jun 27, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $4.70 | +453.19% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $1.66 | +803.61% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $1.04 | +765.38% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $31.15 | +115.09% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $27.16 | +290.28% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $0.52 | +4,526.95% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $7.24 | +728.73% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $52.95 | -15.01% | 1 | Nov 2, 2023 |
CRISPR Therapeutics AG
Jun 27, 2025
Downgrades: Hold
Price Target: $45
Current: $47.49
Upside: -5.24%
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $4.70
Upside: +453.19%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.66
Upside: +803.61%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.04
Upside: +765.38%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $31.15
Upside: +115.09%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $27.16
Upside: +290.28%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $0.52
Upside: +4,526.95%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $7.24
Upside: +728.73%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $52.95
Upside: -15.01%